Full Press Release Details
Cellectar Biosciences to Host 2017 Financial
Results and Business Update Conference Call on March 22, 2018
MADISON, Wis. (March 19, 2018) - Cellectar Biosciences
(Nasdaq: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs
for the treatment of cancer, today announces that management will host a teleconference and live webcast to report financial results
for the 12 months ended December 31, 2017 and to provide a business update on Thursday, March 22, 2018 at 8:30 AM ET.
Interested investors may participate in
the conference call by dialing 844-751-1093 (US domestic) or 574-990-2954 (international) and providing conference ID 6674595,
or participate via webcast at https://edge.media-server.com/m6/p/ehq7d7vj. The live and archived webcast can be accessed via the
company's website at investor.cellectarbiosciences.com/events-and-presentations.
For those unable to participate in the live conference call
or webcast, a replay will be available beginning March 22, 2018 two hours after the close of the conference call. To access the
replay, dial 855-859-2056 or 404-537-3406. The replay passcode is 6674595.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is focused on the discovery, development
and commercialization of drugs for the treatment of cancer. The company plans to develop proprietary drugs independently and through
research and development (R&D) collaborations. The core drug development strategy is to leverage our Phospholipid Drug Conjugate
(PDC) platform to develop therapeutics that specifically target treatment to cancer cells. Through R&D collaborations, the
company's strategy is to generate near-term capital, supplement internal resources, gain access to novel molecules or payloads,
accelerate product candidate development and broaden our proprietary and partnered product pipelines.
The company's lead PDC therapeutic, CLR 131, is in a Phase 1
clinical study in patients with relapsed or refractory (R/R) multiple myeloma (MM) and a Phase 2 clinical study in R/R MM and a
range of B-cell malignancies. In 2018 the company plans to initiate a Phase 1 study with CLR 131 in pediatric solid tumors and
lymphoma, and a second Phase 1 study in combination with external beam radiation for head and neck cancer. The company's
product pipeline also includes two preclinical PDC chemotherapeutic programs (CLR 1700 and 1900) and partnered assets include PDCs
from multiple R&D collaborations.
For more information please visit www.cellectar.com.
Forward-Looking Statement Disclaimer
This news release contains forward-looking statements.
You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate,"
"intend," "could," "estimate," "continue," "plans," or their negatives or cognates.
These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause
actual future experience and results to differ materially from the statements made. These statements are based on our current
beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk.
Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional
capital, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds,
the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government
regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from
other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties
related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form
10-K for the year ended December 31, 2016. These forward-looking statements are made only as of the date hereof, and
we disclaim any obligation to update any such forward-looking statements.
LHA Investor Relations